128 related articles for article (PubMed ID: 9815665)
21. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
22. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
23. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
Liu J; Campbell M; Guo JQ; Lu D; Xian YM; Andersson BS; Arlinghaus RB
Oncogene; 1993 Jan; 8(1):101-9. PubMed ID: 8423987
[TBL] [Abstract][Full Text] [Related]
24. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
25. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
LaMontagne KR; Hannon G; Tonks NK
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14094-9. PubMed ID: 9826659
[TBL] [Abstract][Full Text] [Related]
26. Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling.
Takaoka A; Tanaka N; Mitani Y; Miyazaki T; Fujii H; Sato M; Kovarik P; Decker T; Schlessinger J; Taniguchi T
EMBO J; 1999 May; 18(9):2480-8. PubMed ID: 10228162
[TBL] [Abstract][Full Text] [Related]
27. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
Campbell ML; Li W; Arlinghaus RB
Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
[TBL] [Abstract][Full Text] [Related]
28. P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2.
Wilson-Rawls J; Liu J; Laneuville P; Arlinghaus RB
Leukemia; 1997 Apr; 11 Suppl 3():428-31. PubMed ID: 9209414
[TBL] [Abstract][Full Text] [Related]
29. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
30. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Quackenbush RC; Reuther GW; Miller JP; Courtney KD; Pear WS; Pendergast AM
Blood; 2000 May; 95(9):2913-21. PubMed ID: 10779439
[TBL] [Abstract][Full Text] [Related]
32. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
Burgess GS; Williamson EA; Cripe LD; Litz-Jackson S; Bhatt JA; Stanley K; Stewart MJ; Kraft AS; Nakshatri H; Boswell HS
Blood; 1998 Oct; 92(7):2450-60. PubMed ID: 9746785
[TBL] [Abstract][Full Text] [Related]
33. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; GodÃnez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
Miething C; Mugler C; Grundler R; Hoepfl J; Bai RY; Peschel C; Duyster J
Leukemia; 2003 Sep; 17(9):1695-9. PubMed ID: 12970766
[TBL] [Abstract][Full Text] [Related]
35. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
[TBL] [Abstract][Full Text] [Related]
36. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway.
Tauchi T; Yoshimura A; Ohyashiki K
Exp Hematol; 2001 Mar; 29(3):356-61. PubMed ID: 11274764
[TBL] [Abstract][Full Text] [Related]
37. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.
Pendergast AM; Gishizky ML; Havlik MH; Witte ON
Mol Cell Biol; 1993 Mar; 13(3):1728-36. PubMed ID: 8441409
[TBL] [Abstract][Full Text] [Related]
38. Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state.
Briscoe J; Rogers NC; Witthuhn BA; Watling D; Harpur AG; Wilks AF; Stark GR; Ihle JN; Kerr IM
EMBO J; 1996 Feb; 15(4):799-809. PubMed ID: 8631301
[TBL] [Abstract][Full Text] [Related]
39. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
Klejman A; Schreiner SJ; Nieborowska-Skorska M; Slupianek A; Wilson M; Smithgall TE; Skorski T
EMBO J; 2002 Nov; 21(21):5766-74. PubMed ID: 12411494
[TBL] [Abstract][Full Text] [Related]
40. Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha.
Yu CR; Lin JX; Fink DW; Akira S; Bloom ET; Yamauchi A
J Immunol; 1996 Jul; 157(1):126-37. PubMed ID: 8683106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
